Biosite® Inc. Web Site -- TOX Drug Screen -- TOX Drug Screen

By: Alere  09-12-2011

Triage® TOX Drug Screen

The Future of Point-of-Care Testing

The Value of Point-of-Care Drug Testing
Nearly every day patients are treated in emergency departments (ED) across the country for complications due to drug overdose. Attempting to identify the cause of the symptoms as drug-related and non-drug-related can cause considerable stress for ED physicians.

Rapid point-of-care drug testing with the Triage TOX Drug Screen makes sense to the ED:

  • Improves patient care, and/or
  • Reduces the expenses associated with additional diagnostic testing or unnecessary admissions

According to the National Academy of Clinical Biochemistry (NACB), Laboratory Medicine Practice Guidelines (LMPG), stat toxicology assays required to support an ED should have a turnaround time of one hour or less. The Triage TOX Drug Screen provides rapid results at the point-of-care in approximately 15 minutes.

A Breakthrough in Point-of-Care Drug Testing

Biosite Introduced the Triage Drugs of Abuse Panel in 1992
Introduced in 1992, the Triage Drugs of Abuse Panel was Biosite’s first rapid diagnostic test. Biosite subsequently introduced the first urine tricyclic antidepressants (TCA) application with the launch of Triage Plus TCA. Biosite’s Triage Drugs of Abuse Panels are used in more than 2,300 hospitals nationwide. That’s nearly 50 percent of all U.S. hospitals.


Other products and services from Alere

09-12-2011

Biosite® Inc. Web Site -- Cardiac Panel

Finally, technology that has caught up with your needs.Rapid, quantitative measurement of CK-MB, myoglobin, and troponin I to aid in the diagnosis of acute myocardial infarction. Rapid, actionable information to aid in the diagnosis of acute myocardial infarction. Enables triage decisions in under two hours when used with accelerated protocol 1. Simultaneous cardiac marker results from whole blood in approximately 15 minutes.


09-12-2011

Biosite® Inc. Web Site -- D-Dimer Test

A rapid, quantitative immunoassay to aid in the assessment and evaluation of patients suspected of having disseminated intravascular coagulation and thromboembolic events including pulmonary embolism and deep vein thrombosis. Performed on the Triage Meters.


09-12-2011

Biosite® Inc. Web Site -- Products

Through combined expertise in diagnostic discovery and commercialization, Biosite is focused on developing novel diagnostics tests that are capable of immediately and accurately diagnosing and assessing critical conditions, which can take several hours or even days using conventional testing methods.


09-12-2011

Biosite® Inc. Web Site -- Profiler Shortness of Breath

The Triage® Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment of patients with acute coronary syndromes. Troponin I, CK-MB, myoglobin, BNP and D-dimer each provide unique clinical information, and the panel approach maximizes the strengths of each marker.


09-12-2011

Biosite® Inc. Web Site -- Triage System

An immunoassay for use as an aid in the diagnosis of acute myocardial infarction, the diagnosis and assessment of severity of congestive heart failure, and the risk stratification of patients with acute coronary syndromes and congestive heart failure. An immunoassay for the quantitative determination of CK-MB, myoglobin, and troponin I in whole blood or plasma, as an aid in the diagnosis of acute myocardial infarction.


09-12-2011

Biosite® Inc. Web Site -- Triage® BNP Test

The Triage BNP Test is intended for use with the Triage Meters for the rapid in vitro quantitative measurement of B-Type Natriuretic Peptide in human whole-blood or plasma specimens using EDTA as the anticoagulant. 98 percent diagnostic accuracy in initial studies versus all other clinical findings in patients with or without disease history3.